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Abstract: A 33-year-old woman with Hodgkin disease Ann Arbor stage
IIA underwent baseline 18F-FDG PET/CT scanning. The scan showed
gross multicystic enlargement of both ovaries and a nodule at the edge of
the right ovary with intense FDG uptake (SUVmax = 14.8). Differential di-
agnosis would include ovarian lymphoma manifestation, endometrioma,
and ovarian or pelvic neoplasia. However, chart analysis revealed previous
superstimulation with gonadotropins and gonadotropin release hormone
antagonist, and transvaginal oocyte retrieval the day before FDG PET/CT.
This led to the diagnosis of ovarian hyperstimulation syndrome, with the
FDG-avid focus representing a hemorrhagic follicle after transvaginal oo-
cyte retrieval procedure.
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FIGURE 2. Three weeks later, the “low-dose”CT scan (A) of FDG PET/CT showed bilateral hypodense cysticmasses in the pelvis,
representing grossly enlarged ovaries (arrowheads), normal-sized uterus (asterisk), and a small amount of pelvic fluid. The
coronal MIP PET image (B) delineated bilateral faint and patchy FDG uptake of the ovaries (orange arrowheads), with one focus
of intense uptake (orange arrow; SUVmax 14.8) situated at the edge of the right ovary, as seen on the corresponding
transverse FDG PET/CT image (C; intense focus, black arrow; enlarged stimulated ovaries, encircled with dotted line); TVOR had
been performed the day before the FDG PET/CT scan. Ultrasound-guided TVOR is a technique used for in vitro fertilization as
part of assisted reproductive therapy (ART) procedures. Doubling over the last decade, ART has become a popular treatment for
infertility, being responsible for approximately 1.5% of live births in the United States in 2011.1 Young oncological patients
undergo this procedure for fertility preservation. For TVOR, all accessible follicles are aspirated. Complications of the procedure
are unusual. If occurring, they can lead to iatrogenic ovarian hyperstimulation syndrome (OHSS), taking a severe course in
approximately 1%.2 Serious clinical conditions include hemoconcentration, thromboembolism, renal failure, and adult
respiratory distress syndrome.3–5 An ovarian manifestation of Hodgkin disease is among the differential diagnoses for new
metabolically active pelvic lesions. Such would change the Ann Arbor stage from IIA to IV in our patient. Secondary ovarian
involvement in lymphoma is more common than primary involvement, both being mainly seen with non-Hodgkin
lymphoma.6,7 Other differential diagnoses for FDG-avid ovarian lesions are endometrioma, primary and secondary ovarian
malignancy, and corpus luteum cyst.8–17
FIGURE 1. An initial CT scan 3 weeks before the FDG PET/CT
scan showed no subdiaphragmal lymphomamanifestation,
ascites, or pelvic mass. Both ovaries were normal in size and
morphology (black arrows).
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FIGURE 3. FDG PET/CT imaging features were in line with
transvaginal ultrasound: the follicular hyperplasia within the
enlarged ovaries (white arrowheads) corresponded to the
typical “spoke wheel” pattern of stimulated ovaries.18 Our
patient hadmild tomoderate clinical symptoms of OHSS. The
FDG-avid focus seen on PET/CT corresponded to prominent
clotting due to postprocedural hemorrhagic changes in one
enlarged follicular cyst within the right ovary (white arrow),
whereas all other follicle cysts showed only mild signs of
hemorrhage. One recent report describes changes after
TVOR and ovarian stimulation, confirming diffuse FDG uptake
in bilaterally enlarged ovaries.19 Our case additionally
demonstrates that foci of intense uptake might occur shortly
after the procedure and represent clotting at the site of
follicle aspiration. The imaging pattern of bilaterally enlarged
ovaries containing an FDG-avid focus in the setting of a
young female oncologic patient scanned before the start of
chemotherapy should therefore raise the suspicion of
previous ovarian stimulation and TVOR, and should not be
confounded with an ovarian manifestation of the
oncologic illness.
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